Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Disease × Albumin-Bound Paclitaxel × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 34 Breast Neoplasms 11 Carcinoma, Non-Small-Cell Lung 10 Neoplasms 9 Neoplasm Metastasis 8 Lung Neoplasms 4 Esophageal Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 3 Sarcoma 3 Breast Neoplasms, Male 3 Adenocarcinoma 3 Urinary Bladder Neoplasms 2 Triple Negative Breast Neoplasms 2 Stomach Neoplasms 2 Small Cell Lung Carcinoma 2 Recurrence 2 Pancreatic Diseases 2 Metastatic Pancreatic Adenocarcinoma 2 Melanoma 2 Carcinoma 2 Advanced Solid Tumor 2 Tongue Neoplasms 1 Thymus Neoplasms 1 Solid Cancer 1 Sarcoma, Ewing 1 Rhabdomyosarcoma 1 Prostatic Neoplasms 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Pancreatic cancer, adult 1 Ovarian Neoplasms 1

Interventions

carfilzomib 2 Dexamethasone 2 Cyclophosphamide 2 tivozanib 1 tislelizumab 1 pembrolizumab 1 neratinib 1 Nivolumab 1 Interleukin-15 1 Gemcitabine 1 Erlotinib Hydrochloride 1 Cisplatin 1 Capecitabine 1 Calcium Dobesilate 1 Bevacizumab 1 Albumin-Bound Paclitaxel 1 3-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01730222 2017-09-01

PACT-19

IRCCS San Raffaele

Phase 1/2 Completed

Gastrointestinal

Disease, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡